Results 21 to 30 of about 3,797 (192)

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C [PDF]

, 2016
Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir.
Mitchell, Kisha A, Jakab, Simona, Oikonomou, Ioannis, Lim, Joseph K, Sarkar, Souvik   +4 more
core   +1 more source

The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report

Annals of Hepatology, 2018
Chronic hepatitis C virus (HCV) infection can be cured with treatment using direct-acting antivirals (DAAs). Although these drugs have been widely studied, information about certain special populations is missing.
Elise J. Smolders, Sophie B. Willemse, Omar El-Sherif, Saye Khoo, David M. Burger   +4 more
doaj   +1 more source

Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases, 2018
Background and study aim: Recently, multiple regimens of different direct-acting antiviral agents (DAAs) have been emerged. We aimed to assess the efficacy, safety and improvement of liver profile for patients treated with regimens of direct acting ...
Ahmed Gaber, Amany Moustafa, Mohammed Elhamouly, Mohamed Fathallah   +3 more
doaj   +1 more source

Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study.

, 2023
BackgroundThe Simeprevir ObservatioNal Effectiveness across practice seTtings (SONET) study evaluated the real-world effectiveness of simeprevir-based treatment for hepatitis C virus (HCV) infection.MethodsThe SONET study was a phase 4, prospective ...
Prabhakar, Avinash, Villadiego, Shirley, Manch, Richard, Alam, Imtiaz, DeMasi, Ralph, Reindollar, Robert, Forlenza, Jamie, Brown, Kimberley, Donovan, Cynthia, Lauwers, Kris, Mah'moud, Mitchell A, Mohanty, Smruti R, Tandon, Neeta, Naggie, Susanna, Slim, Jihad   +14 more
core   +1 more source

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION

Журнал инфектологии, 2017
The incidence of chronic hepatitis C inRussiais extremely high, that requires an increase the access to effective treatment regimens.The aim of the study is to assess the cost of HCV therapy (genotype 1) of naïve patients without cirrhosis with second ...
A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin   +4 more
doaj   +1 more source

Borylcyclopropanes: Synthetic Strategies and Applications

Angewandte Chemie, Volume 138, Issue 37, 7 September 2026.
Borylcyclopropanes (cyclopropanes bearing a boron substituent) sit at the intersection of two privileged frameworks in synthesis. This review provides the first exhaustive survey of their chemistry, spanning metal–carbene, nucleophilic cyclization, radical, hydroboration, and C─H activation routes, and documenting applications in medicinal chemistry ...
Aiza A. Butt, Joseph M. Ready
wiley   +2 more sources

Simultaneous spectrofluorimetic determination of remdesivir and simeprevir in human plasma

Scientific Reports, 2022
As new infectious mutations of SARS-CoV-2 emerged throughout the world, innovative therapies to counter the virus-altered drug sensitivities were urgently needed.
Mona E. El Sharkasy, Manar M. Tolba, Fathalla Belal, Mohamed I. Walash, Rasha Aboshabana   +4 more
doaj   +1 more source

Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus

Gut and Liver, 2017
Background/AimsThe present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic ...
Hideyuki Tamai, Yoshiyuki Ida, Akira Kawashima, Naoki Shingaki, Ryo Shimizu, Kosaku Moribata, Tetsushi Nasu, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano   +11 more
doaj   +1 more source

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms

Molecules, 2020
A simple, rapid, sensitive, and precise reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of four direct-acting antivirals, sofosbuvir (SF), ledipasvir (LD), declatasvir (DC), and simeprevir (SM),
Essam Ezzeldin, Nisreen F. Abo-Talib, Marwa H. Tammam, Yousif A. Asiri, Abd El-Galil E. Amr, Abdulrahman A. Almehizia   +5 more
doaj   +1 more source

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study

Health Science Reports, 2020
Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment.
Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil   +10 more
doaj   +1 more source